Cancer Advisor

Quick Answer Dr. Thomas Seyfried , a biologist at Boston College, argues that cancer is primarily a mitochondrial metabolic disease rather than a genetic one. His core treatment framework — the Press-Pulse protocol — pairs a therapeutic ketogenic diet that restricts glucose and glutamine (the "press") with pulsed adjuncts like glutaminase-inhibiting drugs, hyperbaric oxygen, or fasting (the "pulse"). Mechanistic and preclinical evidence is strong; human evidence is a mix of promising case reports and small, mostly inconclusive trials — including a 2026 randomized pancreatic cancer trial that showed a survival trend without reaching statistical significance. Most integrative oncologists treat metabolic therapy as a physician-supervised adjunct to, not a replacement for, standard cancer care. In This Guide Who Is Thomas Seyfried? The Case Against Standard-of-Care Statistics Diet and Cancer: Why Food Isn't Neutral Cutting Off Cancer's Fu...

Abstract The metabolic theory of cancer, popularized by Thomas Seyfried, proposes that cancer is fundamentally a disease of mitochondrial dysfunction and altered energy metabolism rather than solely a genetic disorder. Building upon the pioneering work of Otto Warburg, Seyfried argues that many cancer cells depend heavily on glucose fermentation and glutamine metabolism due to impaired oxidative phosphorylation. This article reviews the scientific basis of Seyfried’s metabolic theory, including the Warburg effect, ketogenic metabolic therapy, fasting, mitochondrial dysfunction, hyperbaric oxygen therapy, and emerging concepts involving lipid metabolism, carbon dioxide physiology, and oxidative stress. We also examine criticisms, limitations, and future directions in metabolic oncology research. Introduction Cancer research has traditionally focused on genetic mutations as the primary drivers of tumor development. However, a growing body of research suggests that metabolic dysfunction m...

Ketogenic Therapy Decision Algorithm PATIENT CONSIDERED FOR KETOGENIC THERAPY ↓ Step 1: Anatomic & Tissue Risk Screening Small Intestine / FAP High mucosal lipid exposure Primary small bowel tumors Outcome: HIGH FAO RISK ➔ Direct to Alternative Protocol All Other Primary Sites CNS, Colon, Lung, Head & Neck, Breast, Prostate Outcome: Low immediate mucosal risk ➔ Proceed to Step 2 ↓ Step 2: Genomic & Pathway Profiling High FAO Vulnerability APC mutation / loss CPT1A overexpression Upregulated PPARα/δ pathways Outcome: HIGH FAO RISK ➔ Direct to Alternative Protocol Glycolytic ...